2022 American Transplant Congress
Tumor Suppressor Role of the Caveolar α1-na/k-atpase Signalosome in Nash Related Hepatocellular Carcinoma (HCC)
*Purpose: HCC is the second and fastest-growing cause of cancer- related mortality worldwide, with an estimate of 0.84million cases/year. In the Western countries, due to…2022 American Transplant Congress
Impacts Of Donor Gender On Recurrent Hepatocellular Carcinoma In Liver Transplant Donated After Brain Death
*Purpose: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. It is well known that HCC is predominant in males and prognosis…2022 American Transplant Congress
Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality
*Purpose: Liver transplant candidates with hepatocellular carcinoma (HCC) risk tumor progression that may disqualify them from transplant eligibility while awaiting HCC exception points on the…2022 American Transplant Congress
The Feasibility of Changing HCC MELD Exception Criteria to an Exclusive DCD-Only Option: A Strategy to Increase DCD Utilization
Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX
*Purpose: Outcomes of DCD liver transplantation is comparable to DBD but routine utilization of DCD liver grafts is surprisingly uneven in the US. A more…2022 American Transplant Congress
Surging Liver Transplant Rates for Alcohol-Associated Liver Disease May Exacerbate Waitlist Death of Patients with Hepatocellular Carcinoma in MMAT-3 Era
*Purpose: Rates of liver transplantation (LT) for alcohol-associated liver disease (ALD) have increased significantly, in part related to broader acceptance of severe alcohol hepatitis (AH)…2022 American Transplant Congress
Disparities in Liver Transplant Access for HCC Patients Based on Patient Blood Type and the Intensity of Competition for Organs Under MMAT-3
University of Southern California, Los Angeles, CA
*Purpose: Recent policy changes (acuity circles and MMAT-3 for HCC MELD exception) aimed to reduce geographic disparities in access to liver transplant (LT) and mitigate…2022 American Transplant Congress
Exploring Individual Optimal Immunosuppression Management According to the Oncological Risk in Liver Transplanted Patients with Hepatocellular Carcinoma
*Purpose: Post-Liver transplant (LT) immunosuppression management is the only modifiable factor to prevent hepatocellular carcinoma (HCC) recurrence; however, the impact of immunosuppression on the HCC…2022 American Transplant Congress
The Effect of Adoption of Acuity Circles on Hepatocellular Carcinoma Transplantation Rates at a Single High Acuity Center
*Purpose: Transplantation for selected patient with HCC has been prioritized with a MELD exception since 2002. Further changes have decreased the maximum exception for HCC.…2022 American Transplant Congress
Center-Level Variability in DDLT Rate Before and After the Implementation of MMaT/250 Score
Johns Hopkins Medical Institutions, Baltimore, MD
*Purpose: In 02/2020, OPTN replaced DSA/regional boundaries with acuity circles and substituted exception scores for individual patients to median-MELD-at-transplant within 250 nautical miles of a…2022 American Transplant Congress
Cell-free Amniotic Fluid Reduces Liver Inflammation And Fibrosis
*Purpose: Effective interventions for hepatic inflammation and fibrosis remain a dire unmet need in transplant medicine. Cell-free amniotic fluid (AF) represents a potential alternative to…
- 1
- 2
- 3
- …
- 23
- Next Page »